NCT03288792 is a NA clinical trial of RI8 device imaging in Breast Cancer, sponsored by Real Imaging Ltd..

Who is sponsoring NCT03288792?

NCT03288792 is sponsored by Real Imaging Ltd..

What drugs are being tested in NCT03288792?

Interventions in NCT03288792: RI8 device imaging.

What condition does NCT03288792 study?

NCT03288792 studies Breast Cancer.

Is NCT03288792 still recruiting?

NCT03288792 is currently terminated. Last updated 3 May 2019.

Last reviewed 2019-05-03 · How we verify

NCT03288792

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Evaluation of 3D Functional MIRA System in Women With Mammographically Dense Breasts

Terminated NA Last updated 3 May 2019

What this trial tests

NA trial testing RI8 device imaging in Breast Cancer in 435 participants. Terminated before completion.

Timeline

15 April 2018

Primary endpoint
9 April 2019

30 April 2019

Quick facts

Lead sponsor	Real Imaging Ltd.
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	435
Start date	15 April 2018
Primary completion	9 April 2019
Estimated completion	30 April 2019
Sites	5 locations across United States

Drugs / interventions tested

RI8 device imaging

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Real Imaging Ltd.

Who can join

Adults 40 to 70, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this image acquisition study is to compare, in a Reader Study, the RI8 system used in conjunction with a conventional mammography to mammography alone, and to determine whether the addition of supplementary RI8 result will improve ROC area under the curve. The study is prospective, multi-center, sequential, control trial with the woman serving as her own control. Women determined to have heterogeneously or extremely dense breast based on her previous mammogram and are undergoing routine screening mammography at one of the clinical sites assigned for this study will be eligible to join the study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03288792 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Real Imaging Ltd.
Last refreshed: 3 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03288792.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing